Dr. Agarwal's Health Care Limited (NSE:AGARWALEYE) announced its Q1 FY2027 unaudited consolidated financial results on 4 August 2026, reporting revenue from operations of Rs 614 crore, EBITDA of Rs 177 crore, and profit after tax of Rs 55 crore, all on a consolidated basis.
Key Highlights
- Consolidated revenue from operations rose 26.0% year-on-year to Rs 614 crore for the quarter ended June 30, 2026.
- Consolidated PAT grew 44.6% year-on-year to Rs 55 crore, with a PAT margin of 8.9% versus 7.6% in Q1 FY26.
- The company added 18 new facilities in the quarter, including a record 16 new surgical facilities, bringing the total network to 304 facilities across 10 countries.
- The board approved the appointment of S.R. Batliboi and Associates LLP as statutory auditors until the 20th AGM, and KPMG Assurance and Consulting Services LLP as internal auditors for FY2026-27, subject to member approval where applicable.
About the Company
Dr. Agarwal's Health Care Limited, headquartered in Chennai, is India's largest eye care service chain by revenue from operations for FY25, per CRISIL Intelligence. Listed on NSE under the ticker AGARWALEYE, it operates 304 facilities across 14 states and 5 union territories in India, and 19 facilities across nine countries in Africa, offering surgeries, consultations, diagnostics, and optical products.
Announcement in Detail
The board meeting, held on 4 August 2026 from 11:50 a.m. to 1:45 p.m. IST, approved the unaudited consolidated and standalone financial results for Q1 FY2027. Consolidated revenue from operations stood at Rs 614 crore (up 26.0% YoY), total income at Rs 620 crore (up 23.9% YoY), EBITDA at Rs 177 crore (up 25.2% YoY, margin 28.5%), and PAT at Rs 55 crore (up 44.6% YoY). India revenue from operations was Rs 552 crore, up 25.3% YoY. The company performed 91,082 surgeries during the quarter, a 15.5% YoY increase.
Additionally, the board approved the appointment of M/s. S.R. Batliboi and Associates LLP as statutory auditors from the conclusion of the 16th AGM until the 20th AGM, subject to member approval. M/s. KPMG Assurance and Consulting Services LLP was appointed as internal auditors for FY2026-27. M/s. B Y and Associates was re-appointed as cost auditors for FY2026-27. Separately, the board noted that Orbit Healthcare Services (Mauritius) Limited, a direct wholly owned subsidiary, has proposed to incorporate a wholly owned subsidiary in Nigeria, pending all necessary regulatory and governmental approvals under applicable Nigerian and Mauritius laws.
Impact on Investors
The filing shows consistent margin performance, with EBITDA margin at 28.5% compared to 28.2% in Q1 FY26, even as the company commissioned 23 surgical greenfield facilities over the preceding six months. Shareholders will observe that PAT margin improved to 8.9% from 7.6% in the prior year period, indicating operating leverage at the consolidated level.
Investors will note that the proposed Nigeria subsidiary incorporation is subject to regulatory approvals in both Nigeria and Mauritius and is at an early stage. The transition of statutory auditors from the 16th AGM requires formal member approval; until that approval is obtained, it remains a board recommendation, not a concluded appointment.
Sector / Market Context
India's eye care services segment is shaped by a large unmet need: the National Programme for Control of Blindness and Visual Impairment data has consistently highlighted cataract as the leading cause of blindness in India. Organised eye care chains have been scaling hub-and-spoke networks to address Tier-II and Tier-III city demand, a structural trend reflected in the company's disclosure that 191 of its India facilities are located outside Tier-I cities.